This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over 12 cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, cerebrospinal fluid (CSF) examination and brain biopsy.
CITATION STYLE
Devlin, M., Swayne, A., Newman, M., O’Gorman, C., Brown, H., Ong, B., … Blum, S. (2019). A case of immune-mediated encephalitis related to daclizumab therapy. Multiple Sclerosis Journal, 25(5), 750–753. https://doi.org/10.1177/1352458518792403
Mendeley helps you to discover research relevant for your work.